

## Echocardiography to Manage Acute Submassive PE

David M. Dudzinski MD, FAHA, FACC, FASE  
Tuesday, November 19, 2024

@criticalecho



NO DISCLOSURES

### Appropriate Use Criteria from AHA/ACC/ASE

- **Suspected** [acute] PE in order to **establish** diagnosis
- **Known** acute PE to **guide** therapy (eg, thrombectomy and thrombolytics)


"Rarely appropriate"

"Appropriate"


In patients without haemodynamic instability, use of clinical prediction rules integrating PE severity and comorbidity, preferably the PESI or sPESI, should be considered for the assessment in the acute phase of PE. <sup>10,11,12,13</sup>	IIIa	B
Assessment of the RV by imaging methods <sup>14</sup> or laboratory biomarkers <sup>15</sup> should be considered, even in the presence of a low PESI or a negative sPESI. <sup>16</sup>	IIIa	B

JASE 2011;24:229. EHU 2020;41:543. JASE 2023;36:906.  
PLoS One 2022;17:e0276202 (multiorgan POCUS, 96% Sp, but 50% Sn)

- Integrative assessment of severity
- Continuum – not binary



### Risk Stratification



Insights Imaging 2011;2:705. EHU 2014;35:3033.  
Thromb Haemost. 2008;100:747.  
Circulation 2000;101:2817 & 2011;123:1788

### CT in PE Prognosis

- Size Measures
  - ✓ RV (RV/LV)
  - ± RA
  - ± IVC
  - ± PA
- Functional Measures
  - ? RV systolic function
  - ? Right heart pressures
  - \* McConnell sign; Doppler
  - ± Septal geometry

Dudzinski DM, et al. Acad Emerg Med 2017;3:337.

## Echo in PE Prognosis (“RVS”)

### Size Measures

- RV (RV/LV)
- RA
- IVC
- PA




TABLE 4. Associations with outcome.



Variable	Odds ratio	95% CI	P
Primary outcome (univariate)			
RV/LV in diastole	9.31	4.10-21.48	<.0001
RV/LV in systole	3.97	2.29-6.88	<.0001
FAC	.95	.93-.96	<.0001
Primary outcome (multivariate)			
RV/LV in diastole	9.48	4.12-21.65	<.0001
RV/LV in systole	3.88	2.23-6.74	<.0001

Lubos MD, Dudzinski DM, Kabrhel C. *Emerg Radiol* 2023;30:325

## Echo in PE Prognosis (“RVS”)




### Size Measures

- RV (RV/LV)
- RA
- IVC
- PA



### Functional Measures

- Right heart pressures
- RV systolic function
- McConnell sign
- Septal geometry
- Pulmonary artery Doppler
- LV systolic function (VTI)



Bernard S, Dudzinski DM. *JASE* 2019;32:807. *JASE* 2023;36:906 & 933.  
Munshi SD, Ullrich SA, Dudzinski DM. *JASE* 2023;36:944

## CT v. TTE for Submassive PE

- n=298, age 59 ± 17, 49% ♀, 90% White
- 104 had CT and TTE; 14 had composite outcome

	(-) RVS on CT	5 Day Event	(+) RVS on CT	5 Day Event	Subtotal	
(-) RVS on TTE	25 (24%)	4%	37 (36%)	3%	62 (60%)	3%
(+) RVS on TTE	5 (5%)	20%	37 (36%)	30%	42 (40%)	29%
Subtotal	30 (29%)	7%	74 (71%)	16%	104	

Dudzinski DM, et al. *Acad Emerg Med* 2017;3:337.



## CT v. TTE for Submassive PE

- n=298, age 59 ± 17, 49% ♀, 90% White
- 104 had CT and TTE; 14 had composite outcome

	(-) RVS on CT	5 Day Event	(+) RVS on CT	5 Day Event	Subtotal	
(-) RVS on TTE	25 (24%)	4%	37 (36%)	3%	62 (60%)	3%
(+) RVS on TTE	5 (5%)	20%	37 (36%)	30%	42 (40%)	29%
Subtotal	30 (29%)	7%	74 (71%)	16%	104	

Dudzinski DM, et al. *Acad Emerg Med* 2017;3:337.



## CT in PE Prognosis

### Size Measures

- ✓ RV (RV/LV)
- ± RA
- ± IVC
- ± PA

### Functional Measures

- \* RV systolic function
- ± Right heart pressures
- \* McConnell sign; Doppler
- ± Septal geometry

Among patients with PE and RV strain by CT, positive versus negative TTE predicted 10x greater risk of clinical deterioration.

Dudzinski DM, et al. *Acad Emerg Med* 2017;3:337.



## CT v. TTE for Submassive PE Update

- 2014-2017, PERT patients, > 64 slice CT
- n=554 with both CT and TTE

	(-) RVS on CT	(+) RVS on CT	Subtotal
(-) RVS on TTE	9 (2%)	203 (37%)	212 (38%)
(+) RVS on TTE	18 (3%)	324 (58%)	342 (62%)
Subtotal	27 (5%)	527 (95%)	554

Lynne MD, Dudzinski DM, Kabrhel C. *Emerg Radiol* 2023;30:325.



## CT v. TTE for Submassive PE Update

- 2014-2017, PERT patients, > 64 slice CT
- n=554 with both CT and TTE


	(-) RVS on CT	(+) RVS on CT	Subtotal
(-) RVS on TTE	9 (2%)	203 (37%)	212 (38%)
(+) RVS on TTE	18 (3%)	324 (58%)	342 (62%)
Subtotal	27 (5%)	527 (95%)	554

MASSACHUSETTS  
GENERAL HOSPITAL  
HEART CENTER

Lyhne MD, Dudzinski DM...Kabrnel C. Emerg Radiol 2023;30:325.

## Meta-Analysis of Echocardiographic RV Dysfunction in Normotensive PE


- N=55 (4394 excluded), n=17090, 37.8% RVS
- Odds Ratios:
  - Combined AE 3.29
  - All cause Mortality 2.00
  - PE Mortality 4.01



Eur Resp Rev 2022;31:220120.

## Tricuspid Annular Plane Systolic Excursion

- Measure of longitudinal shortening; *assumes*
  - Local ≈ global function
  - Base reflective of free wall and apex (specifically may *not* be true in disease)
- ↓ TAPSE in acute PE but also RVMI, PAH, CTEPH
- Operator/image dependent but has prognostic info



Am J Respir Crit Care Med 2006;174:1034.  
J Cardiovasc Ultrasound 2012;20:181.  
Eur Respir Rev 2010;19:288.

## Echo: TAPSE in Normotensive Submassive PE Patients

- 411 PE pts
  - Age 64 ± 18
  - 58% submass, 41% low risk
  - 2% lytic
- Hours to TTE
  - Admit: 193
  - <24h: 159
  - <72h: 59
- TAPSE ≤ 15
  - 20 % PPV
  - 99 % NPV






Figure 3. Kaplan-Meier Survival Analysis According to TAPSE in 411 Initially Normotensive Patients With APE

JACC Imaging 2014;7:553


## Echo: RV-PA Coupling



## Echo: RV-PA Coupling



## RV-PA Coupling: TAPSE/PASP Ratio




Lyhne M, Kabrheil C...Dudzinski DM. *EHI: CV Imaging* 2021;22:285. *EHI Open* 2022;2:oeac007.



## Putting it All Together ?

**Table 5** Multivariable models relating various clinical and echocardiographic variables to the primary outcome in patients with PE

Models	AUC
Admission Trn + BNP	0.73
Echo RVFWS + RV S' + TAPSE/RVSP	0.769
CT RV/LV + thrombus burden + septal bowing	0.796
CT RV/LV + thrombus burden + RVFWS + RV S' + Trn + BNP	0.857
CT RV/LV + thrombus burden + RVFWS + RV S' + TAPSE/RVSP + Trn + BNP	0.893



*EHI* 2022;23:oeac007 and 008



## Summary: Echo in Submassive PE

- **Prognostics: Echocardiography in PE adds**
  - ↑ **Sn for RVS:** NPV for adverse events
  - ↑↑ **Sp for RVS:** PPV to appropriately target invasive interventions prospectively (risk-benefit calculations)
    - You need echocardiography if possibly considering an intervention
    - **which means most intermediate-high risk PE**
- Remember, Echocardiography also:
  - Informs differential (cancer, RVMl, shunting) and chronicity
  - Establishes baseline (to assess impact of intervention)
  - Assists with procedural planning and guidance (chamber size/navigation, anatomy, clot-in-transit)
  - Help if need to consider MCS



## Echocardiography to Manage Acute Submassive PE

David M. Dudzinski MD, FAHA, FACC, FASE  
@criticalecho

